The evidence discussed indicates aberrant immune function in MS. The abnormalities in T-cell subsets, especially in S cells, present opportunities, in the authors' opinion, for therapeutic intervention. What is required, the authors believe, is a systematic testing of pharmacologic agents for their efficacy as specific stimulators of S-cell function. Were it possible to discover such an agent, it might prove useful in the symptomatic treatment of flareups of MS. In addition, in patients with slowly progressive disease and even in those with seemingly quiescent disease (which, for reasons given above may not, in fact, be quiescent), augmented S-cell function might lessen progression of disability. Finally, the study of helper cell function in MS should be undertaken in a systematic manner. Conceivably, an agent which specifically blocked helper cell function might exert a beneficial effect in flareups of MS and, if combined with a stimulator of S-cell function, could profoundly tip the balance of the immune response in favor of remission.
|Original language||English (US)|
|Number of pages||5|
|Issue number||9 II|
|State||Published - 1978|
ASJC Scopus subject areas